



Edition: BP 2025 (Ph. Eur. 11.6 update)

## Gabapentin Tablets

### [General Notices](#)

### Action and use

Antiepileptic.

## DEFINITION

Gabapentin Tablets contain Gabapentin.

*The tablets comply with the requirements stated under Tablets and with the following requirements.*

### Content of gabapentin, $C_9H_{17}NO_2$

95.0 to 105.0% of the stated amount.

## IDENTIFICATION

The [infrared absorption spectrum](#) of the powdered tablets collected in ATR mode, [Appendix II A](#), is concordant with the reference spectrum obtained with [gabapentin EPCRS](#).

## TESTS

### Dissolution

Comply with the [dissolution test for tablets and capsules](#), [Appendix XII B1](#).

#### TEST CONDITIONS

- (a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.
- (b) Use 900 mL of 0.1M [hydrochloric acid](#), at a temperature of 37°, as the medium.

#### PROCEDURE

Carry out the method for [liquid chromatography](#), [Appendix III D](#), using the following solutions.

- (1) After 45 minutes withdraw a sample of the medium and filter. Use the filtered medium, diluted with dissolution medium if necessary, to produce a solution expected to contain 0.011% w/v of Gabapentin.
- (2) 0.011% w/v of [gabapentin EPCRS](#) in 0.1M [hydrochloric acid](#).
- (3) 0.033% w/v of [gabapentin EPCRS](#) and 0.0016% w/v of [gabapentin impurity A EPCRS](#) in the medium.

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (25 cm × 4.6 mm) packed with octadecylsilyl [silica gel](#) (5 µm) (Hypersil ODS is suitable).
- (b) Use isocratic elution and the mobile phase described below.

- (c) Use a flow rate of 1 mL per minute.
- (d) Use an ambient column temperature.
- (e) Use a detection wavelength of 210 nm.
- (f) Inject 25 µL of each solution.

#### MOBILE PHASE

1 volume of [orthophosphoric acid](#), 22 volumes of [acetonitrile R1](#), 78 volumes of [methanol R1](#) and 115 volumes of a solution containing 1% w/v of [ammonium dihydrogen orthophosphate](#) and 0.17% w/v of [sodium decanesulfonate](#) in [water](#). Adjust the pH to 4.4 with [triethylamine](#).

When the chromatograms are recorded under the prescribed conditions, the retention times of gabapentin and impurity A is about 6 minutes and 8.5 minutes respectively.

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the [resolution](#) between the peaks due to gabapentin impurity A and gabapentin is at least 5.0.

#### DETERMINATION OF CONTENT

Calculate the total content of  $C_9H_{17}NO_2$  in the medium from the chromatograms obtained and using the declared content of  $C_9H_{17}NO_2$  in [gabapentin EPCRS](#).

#### LIMITS

The amount of gabapentin released is not less than 75% (Q) of the stated amount.

#### Related substances

Carry out the method for [liquid chromatography](#), [Appendix III D](#), using the following solutions in a mixture of 1 volume of [acetonitrile R1](#) and 9 volumes of [water](#) (solvent A).

- (1) Disperse a quantity of powdered tablets containing 0.5 g of Gabapentin in 20 mL of solvent A. Add a sufficient volume of the solvent A to produce 25 mL and filter.
- (2) Dilute 1 volume of solution (1) to 100 volumes, dilute 1 volume of the resulting solution to 10 volumes.
- (3) 0.02% w/v each of [gabapentin EPCRS](#), [gabapentin impurity A EPCRS](#) and [gabapentin impurity B EPCRS](#).

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (25 cm × 4.6 mm) packed with *dimethyloctylsilane* (5 µm) (Hypersil MOS is suitable).
- (b) Use gradient elution and the mobile phase described below.
- (c) Use a flow rate of 1.5 mL per minute.
- (d) Use an ambient column temperature.
- (e) Use a detection wavelength of 210 nm.
- (f) Inject 50 µL of each solution.

#### MOBILE PHASE

*Mobile phase A* 0.01M [potassium dihydrogen orthophosphate](#) previously adjusted to pH 6.9 with a 10% w/v solution of [potassium hydroxide](#).

*Mobile phase B* [acetonitrile R1](#).

Time (Minutes)	Mobile phase A (% v/v)	Mobile phase B (% v/v)	Comment
0→5	100	0	isocratic
5→15	100→90	0→10	linear gradient
15→45	90→70	10→30	linear gradient
45→55	70→25	30→75	linear gradient
55→60	25	75	isocratic
60→61	25→100	75→0	linear gradient
61→70	100	0	re-equilibration

When the chromatograms are recorded under the prescribed conditions, the retention times relative to gabapentin (retention time about 14 minutes) are: impurity B, about 1.1; impurity A, about 2.6.

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the [resolution](#) between the peaks due to and gabapentin and gabapentin impurity B is at least 1.5.

#### LIMITS

In the chromatogram obtained with solution (1):

the area of any peak corresponding to gabapentin impurity A is not greater than 0.4 times the area of the corresponding peak in the chromatogram obtained with solution (3) (0.4%);

the area of any other [secondary peak](#) is not greater than the area of the principal peak in the chromatogram obtained with solution (2) (0.1%);

the sum of the areas of all the [secondary peak](#) is not greater than 10 times the area of the principal peak in the chromatogram obtained with solution (2) (1.0%);

Disregard any peak with an area less than half the area of the principal peak in the chromatogram obtained with solution (2) (0.05%).

## ASSAY

Weigh and powder 20 tablets. Carry out the method for [liquid chromatography](#), [Appendix III D](#), using the following solutions.

- (1) Shake a quantity of powdered tablets containing 1.25 g of Gabapentin in 150 mL of mobile phase, add sufficient mobile phase to produce 200 mL and filter.
- (2) 0.625% w/v of [gabapentin EPCRS](#) in mobile phase.
- (3) 0.032% w/v each of [gabapentin EPCRS](#) and [gabapentin impurity A EPCRS](#).

#### CHROMATOGRAPHIC CONDITIONS

- (a) Use a stainless steel column (25 cm × 4.6 mm) packed with *octadecylsilylsilica gel* (10 µm) (µBondapak C-18 is suitable).
- (b) Use isocratic elution and the mobile phase described below.
- (c) Use a flow rate of 1 mL per minute.
- (d) Use an ambient column temperature.
- (e) Use a detection wavelength of 210 nm.
- (f) Inject 50 µL of each solution.

#### MOBILE PHASE

10 volumes of [acetonitrile R1](#), 35 volumes of [methanol R1](#), 55 volumes of [water](#) and 0.1 volumes of a mixture containing 0.35% w/v of [potassium dihydrogen orthophosphate](#) and 0.73% w/v of [disodium hydrogen orthophosphate](#) previously adjusted to pH 7.0 with either [orthophosphoric acid](#) or a 10% w/v solution of [potassium hydroxide](#).

When the chromatograms are recorded under the prescribed conditions, the retention times of gabapentin and impurity A are about 3 minutes and 10 minutes respectively.

#### SYSTEM SUITABILITY

The test is not valid unless, in the chromatogram obtained with solution (3), the [\*resolution\*](#) between the peaks due to gabapentin and impurity A is at least 10.0.

#### DETERMINATION OF CONTENT

Calculate the content of  $C_9H_{17}NO_2$  in the tablets using the declared content of gabapentin in [\*gabapentin EPCRS\*](#).

### IMPURITIES

The impurities limited by the requirements of this monograph include impurities A, B and E listed under Gabapentin.